(Q44539058)

English

Syntheses of 3-ethylidenequinuclidine derivatives as squalene synthase inhibitors. Part 2: enzyme inhibition and effects on plasma lipid levels

scientific article published in August 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Syntheses of 3-ethylidenequinuclidine derivatives as squalene synthase inhibitors. Part 2: enzyme inhibition and effects on plasma lipid levels (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

author name string

Tsukasa Ishihara

1

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Hirotoshi Kakuta

2

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Hiroshi Moritani

3

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Tohru Ugawa

4

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Shuichi Sakamoto

5

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Shin ichi Tsukamoto

6

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Isao Yanagisawa

7

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

language of work or name

0 references

publication date

1 August 2003

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Bioorganic & Medicinal Chemistry

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

17

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

3735-3745

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease, 1987 to 1994.

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2803%2900336-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Mortality by cause for eight regions of the world: Global Burden of Disease Study

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2803%2900336-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2803%2900336-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Drug treatment of lipid disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2803%2900336-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of a new hydroxymethylglutaryl-coenzyme A reductase inhibitor, atorvastatin, in patients with combined hyperlipidemia: comparison with fenofibrate.

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2803%2900336-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Pancreatitis and rhabdomyolysis associated with lovastatin-gemfibrozil therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2803%2900336-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Discovery, biosynthesis, and mechanism of action of the zaragozic acids: potent inhibitors of squalene synthase

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2803%2900336-5

7 January 2021

based on heuristic

inferred from DOI database lookup

RPR 101821, a new potent cholesterol-lowering agent: inhibition of squalene synthase and 7-dehydrocholesterol reductase

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2803%2900336-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Synthesis and activity of a novel series of 3-biarylquinuclidine squalene synthase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2803%2900336-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibition of squalene synthase in vitro by 3-(biphenyl-4-yl)-quinuclidine

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2803%2900336-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Syntheses and biological evaluation of novel quinuclidine derivatives as squalene synthase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2803%2900336-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Microsomal metabolism of arylamides by the rat and guinea pig--I. Oxidation of N-3-fluorenylacetamide at carbon-atom-9--a major metabolic reaction

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2803%2900336-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Aryl sulfotransferase IV deficiency in rat liver carcinogenesis initiated with diethylnitrosamine and promoted with N-2-fluorenylacetamide or its C-9-oxidized metabolites.

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2803%2900336-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of simvastatin on receptor mediated metabolism of low density lipoprotein in guinea pigs

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2803%2900336-5

7 January 2021

based on heuristic

inferred from DOI database lookup

YM-53601, a novel squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in several animal species

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2803%2900336-5

7 January 2021

based on heuristic

inferred from DOI database lookup

High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2803%2900336-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2803%2900336-5

7 January 2021

based on heuristic

inferred from DOI database lookup

High-density lipoprotein--the clinical implications of recent studies

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2803%2900336-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2803%2900336-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibition of mammalian squalene synthetase activity by zaragozic acid A is a result of competitive inhibition followed by mechanism-based irreversible inactivation

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2803%2900336-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0968-0896(03)00336-5

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44539058&oldid=2027111241"